JP2006514684A5

JP2006514684A5 -

Download PDF

Info

Publication number: JP2006514684A5
Authority: JP; Japan
Prior art keywords: compound; independently; optionally substituted; hydrogen; halogen
Prior art date: 2003-10-30
Legal status : Withdrawn

Application number

JP2005502202A

Other languages

English (en)

Japanese (ja)

Other versions

JP2006514684A (ja

Filing date

2003-10-30

Publication date

2006-12-21

2003-10-30 Application filed filed Critical

2003-10-30 Priority claimed from PCT/US2003/034319 external-priority patent/WO2004041813A1/en

2006-05-11 Publication of JP2006514684A publication Critical patent/JP2006514684A/ja

2006-12-21 Publication of JP2006514684A5 publication Critical patent/JP2006514684A5/ja

Status Withdrawn legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 claims description 248
239000000203 mixture Substances 0.000 claims description 130
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 107
229910052739 hydrogen Inorganic materials 0.000 claims description 107
239000001257 hydrogen Substances 0.000 claims description 106
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 73
229910052736 halogen Inorganic materials 0.000 claims description 73
150000002367 halogens Chemical class 0.000 claims description 73
201000010099 disease Diseases 0.000 claims description 71
125000001931 aliphatic group Chemical group 0.000 claims description 63
229910052757 nitrogen Inorganic materials 0.000 claims description 60
150000002431 hydrogen Chemical class 0.000 claims description 56
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 53
-1 pyrazol-4-yl Chemical group 0.000 claims description 51
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 47
206010028980 Neoplasm Diseases 0.000 claims description 47
239000011435 rock Substances 0.000 claims description 42
201000011510 cancer Diseases 0.000 claims description 37
125000005842 heteroatom Chemical group 0.000 claims description 37
229920006395 saturated elastomer Polymers 0.000 claims description 37
102000001253 Protein Kinase Human genes 0.000 claims description 36
208000035475 disorder Diseases 0.000 claims description 36
238000000034 method Methods 0.000 claims description 36
108060006633 protein kinase Proteins 0.000 claims description 36
239000003814 drug Substances 0.000 claims description 35
125000004429 atom Chemical group 0.000 claims description 34
230000001404 mediated effect Effects 0.000 claims description 32
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 32
229910052717 sulfur Inorganic materials 0.000 claims description 32
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 31
239000011593 sulfur Substances 0.000 claims description 30
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 29
230000000694 effects Effects 0.000 claims description 29
229910052760 oxygen Inorganic materials 0.000 claims description 29
239000001301 oxygen Substances 0.000 claims description 29
125000000623 heterocyclic group Chemical group 0.000 claims description 27
125000002950 monocyclic group Chemical group 0.000 claims description 25
150000003839 salts Chemical class 0.000 claims description 22
125000001118 alkylidene group Chemical group 0.000 claims description 21
125000004122 cyclic group Chemical group 0.000 claims description 21
125000000217 alkyl group Chemical group 0.000 claims description 20
229940124597 therapeutic agent Drugs 0.000 claims description 20
238000011282 treatment Methods 0.000 claims description 20
229910052799 carbon Inorganic materials 0.000 claims description 19
239000003795 chemical substances by application Substances 0.000 claims description 19
125000003118 aryl group Chemical group 0.000 claims description 17
201000006417 multiple sclerosis Diseases 0.000 claims description 15
125000004433 nitrogen atom Chemical group N* 0.000 claims description 15
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 14
229910052740 iodine Inorganic materials 0.000 claims description 14
208000024827 Alzheimer disease Diseases 0.000 claims description 13
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 13
125000001072 heteroaryl group Chemical group 0.000 claims description 13
208000023275 Autoimmune disease Diseases 0.000 claims description 12
208000010228 Erectile Dysfunction Diseases 0.000 claims description 12
201000001881 impotence Diseases 0.000 claims description 12
208000015122 neurodegenerative disease Diseases 0.000 claims description 12
230000002062 proliferating effect Effects 0.000 claims description 12
208000006673 asthma Diseases 0.000 claims description 11
125000004432 carbon atom Chemical group C* 0.000 claims description 10
125000000753 cycloalkyl group Chemical group 0.000 claims description 10
206010012601 diabetes mellitus Diseases 0.000 claims description 10
229940079593 drug Drugs 0.000 claims description 10
208000020084 Bone disease Diseases 0.000 claims description 9
208000027866 inflammatory disease Diseases 0.000 claims description 9
208000024172 Cardiovascular disease Diseases 0.000 claims description 8
206010020772 Hypertension Diseases 0.000 claims description 8
239000002246 antineoplastic agent Substances 0.000 claims description 8
239000002552 dosage form Substances 0.000 claims description 8
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
208000028867 ischemia Diseases 0.000 claims description 8
125000004076 pyridyl group Chemical group 0.000 claims description 8
230000010410 reperfusion Effects 0.000 claims description 8
230000003612 virological effect Effects 0.000 claims description 8
208000028017 Psychotic disease Diseases 0.000 claims description 7
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
230000002401 inhibitory effect Effects 0.000 claims description 7
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
125000003386 piperidinyl group Chemical group 0.000 claims description 7
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
206010003225 Arteriospasm coronary Diseases 0.000 claims description 6
201000001320 Atherosclerosis Diseases 0.000 claims description 6
208000003890 Coronary Vasospasm Diseases 0.000 claims description 6
201000011634 coronary artery vasospasm Diseases 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 6
208000001286 intracranial vasospasm Diseases 0.000 claims description 6
125000002757 morpholinyl group Chemical group 0.000 claims description 6
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
210000000056 organ Anatomy 0.000 claims description 6
125000004193 piperazinyl group Chemical group 0.000 claims description 6
125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 6
125000004568 thiomorpholinyl group Chemical group 0.000 claims description 6
239000003981 vehicle Substances 0.000 claims description 6
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 5
206010007572 Cardiac hypertrophy Diseases 0.000 claims description 5
206010020880 Hypertrophy Diseases 0.000 claims description 5
108010025020 Nerve Growth Factor Proteins 0.000 claims description 5
206010047163 Vasospasm Diseases 0.000 claims description 5
208000026935 allergic disease Diseases 0.000 claims description 5
210000004413 cardiac myocyte Anatomy 0.000 claims description 5
208000019622 heart disease Diseases 0.000 claims description 5
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
208000030507 AIDS Diseases 0.000 claims description 4
206010002383 Angina Pectoris Diseases 0.000 claims description 4
206010003210 Arteriosclerosis Diseases 0.000 claims description 4
208000020446 Cardiac disease Diseases 0.000 claims description 4
206010059109 Cerebral vasoconstriction Diseases 0.000 claims description 4
208000011231 Crohn disease Diseases 0.000 claims description 4
206010020751 Hypersensitivity Diseases 0.000 claims description 4
208000018737 Parkinson disease Diseases 0.000 claims description 4
208000005107 Premature Birth Diseases 0.000 claims description 4
206010036590 Premature baby Diseases 0.000 claims description 4
201000004681 Psoriasis Diseases 0.000 claims description 4
239000002671 adjuvant Substances 0.000 claims description 4
230000007815 allergy Effects 0.000 claims description 4
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 4
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
230000001900 immune effect Effects 0.000 claims description 4
238000000338 in vitro Methods 0.000 claims description 4
208000037803 restenosis Diseases 0.000 claims description 4
201000000980 schizophrenia Diseases 0.000 claims description 4
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 4
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 3
206010065040 AIDS dementia complex Diseases 0.000 claims description 3
208000019838 Blood disease Diseases 0.000 claims description 3
208000006029 Cardiomegaly Diseases 0.000 claims description 3
201000003883 Cystic fibrosis Diseases 0.000 claims description 3
206010019842 Hepatomegaly Diseases 0.000 claims description 3
208000029462 Immunodeficiency disease Diseases 0.000 claims description 3
206010061218 Inflammation Diseases 0.000 claims description 3
102000007072 Nerve Growth Factors Human genes 0.000 claims description 3
208000001132 Osteoporosis Diseases 0.000 claims description 3
230000001028 anti-proliverative effect Effects 0.000 claims description 3
239000003443 antiviral agent Substances 0.000 claims description 3
230000001066 destructive effect Effects 0.000 claims description 3
208000014951 hematologic disease Diseases 0.000 claims description 3
208000018706 hematopoietic system disease Diseases 0.000 claims description 3
239000003018 immunosuppressive agent Substances 0.000 claims description 3
230000004054 inflammatory process Effects 0.000 claims description 3
239000003900 neurotrophic factor Substances 0.000 claims description 3
208000024891 symptom Diseases 0.000 claims description 3
KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims description 2
201000004384 Alopecia Diseases 0.000 claims description 2
208000014997 Crohn colitis Diseases 0.000 claims description 2
208000023105 Huntington disease Diseases 0.000 claims description 2
208000003782 Raynaud disease Diseases 0.000 claims description 2
208000012322 Raynaud phenomenon Diseases 0.000 claims description 2
229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
229940044683 chemotherapy drug Drugs 0.000 claims description 2
230000003676 hair loss Effects 0.000 claims description 2
230000014511 neuron projection development Effects 0.000 claims description 2
230000003836 peripheral circulation Effects 0.000 claims description 2
XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims description 2
125000006413 ring segment Chemical group 0.000 claims 3
208000019423 liver disease Diseases 0.000 claims 2
239000002260 anti-inflammatory agent Substances 0.000 claims 1
229940121363 anti-inflammatory agent Drugs 0.000 claims 1
230000000561 anti-psychotic effect Effects 0.000 claims 1
239000000164 antipsychotic agent Substances 0.000 claims 1
229940005529 antipsychotics Drugs 0.000 claims 1
239000012829 chemotherapy agent Substances 0.000 claims 1
230000002519 immonomodulatory effect Effects 0.000 claims 1
229940124622 immune-modulator drug Drugs 0.000 claims 1
229940125721 immunosuppressive agent Drugs 0.000 claims 1
229940124589 immunosuppressive drug Drugs 0.000 claims 1
230000003340 mental effect Effects 0.000 claims 1
210000001525 retina Anatomy 0.000 claims 1
125000004434 sulfur atom Chemical group 0.000 claims 1
229940126585 therapeutic drug Drugs 0.000 claims 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 101
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 70
238000005481 NMR spectroscopy Methods 0.000 description 69
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 68
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 66
239000000047 product Substances 0.000 description 52
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 49
239000000243 solution Substances 0.000 description 48
238000006243 chemical reaction Methods 0.000 description 44
239000007787 solid Substances 0.000 description 43
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 41
239000011541 reaction mixture Substances 0.000 description 41
239000002904 solvent Substances 0.000 description 40
108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 39
102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 39
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 38
235000019439 ethyl acetate Nutrition 0.000 description 37
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 36
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 33
238000002360 preparation method Methods 0.000 description 32
239000003112 inhibitor Substances 0.000 description 31
102000001267 GSK3 Human genes 0.000 description 30
210000004027 cell Anatomy 0.000 description 30
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 29
108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 28
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
235000002639 sodium chloride Nutrition 0.000 description 26
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 25
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
150000001412 amines Chemical class 0.000 description 23
0 *C(C(N1C2=C(*)*C(c3c(*)c(*)nc(*)c3*)=S2)=O)N(*)C1=O Chemical compound *C(C(N1C2=C(*)*C(c3c(*)c(*)nc(*)c3*)=S2)=O)N(*)C1=O 0.000 description 22
IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 22
239000012267 brine Substances 0.000 description 21
235000019441 ethanol Nutrition 0.000 description 21
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 21
102000038624 GSKs Human genes 0.000 description 20
108091007911 GSKs Proteins 0.000 description 20
108091000080 Phosphotransferase Proteins 0.000 description 19
108091008611 Protein Kinase B Proteins 0.000 description 19
238000007429 general method Methods 0.000 description 19
102000020233 phosphotransferase Human genes 0.000 description 19
102100034278 Annexin A6 Human genes 0.000 description 18
108090000656 Annexin A6 Proteins 0.000 description 18
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
108010082078 3-Phosphoinositide-Dependent Protein Kinases Proteins 0.000 description 17
102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 17
230000002829 reductive effect Effects 0.000 description 17
YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 16
230000005764 inhibitory process Effects 0.000 description 16
239000000741 silica gel Substances 0.000 description 16
229910002027 silica gel Inorganic materials 0.000 description 16
125000001424 substituent group Chemical group 0.000 description 16
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
230000015572 biosynthetic process Effects 0.000 description 15
239000003921 oil Substances 0.000 description 15
235000019198 oils Nutrition 0.000 description 15
238000003556 assay Methods 0.000 description 14
125000002619 bicyclic group Chemical group 0.000 description 14
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 13
238000000576 coating method Methods 0.000 description 13
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 13
239000002244 precipitate Substances 0.000 description 13
108090000623 proteins and genes Proteins 0.000 description 13
241000894007 species Species 0.000 description 13
102000004190 Enzymes Human genes 0.000 description 12
108090000790 Enzymes Proteins 0.000 description 12
229940088598 enzyme Drugs 0.000 description 12
239000000463 material Substances 0.000 description 12
230000037361 pathway Effects 0.000 description 12
239000000284 extract Substances 0.000 description 11
239000000706 filtrate Substances 0.000 description 11
239000012074 organic phase Substances 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
230000004913 activation Effects 0.000 description 10
230000026731 phosphorylation Effects 0.000 description 10
238000006366 phosphorylation reaction Methods 0.000 description 10
238000002953 preparative HPLC Methods 0.000 description 10
238000010992 reflux Methods 0.000 description 10
229930192474 thiophene Natural products 0.000 description 10
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
102000004877 Insulin Human genes 0.000 description 9
108090001061 Insulin Proteins 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
230000006870 function Effects 0.000 description 9
229940125396 insulin Drugs 0.000 description 9
108090000765 processed proteins & peptides Proteins 0.000 description 9
102000004169 proteins and genes Human genes 0.000 description 9
230000011664 signaling Effects 0.000 description 9
239000000725 suspension Substances 0.000 description 9
238000003786 synthesis reaction Methods 0.000 description 9
CUSJGENRTWNHPV-UHFFFAOYSA-N 4-pyridin-4-yl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=CN=CC=2)=C1 CUSJGENRTWNHPV-UHFFFAOYSA-N 0.000 description 8
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
229960000583 acetic acid Drugs 0.000 description 8
239000002253 acid Substances 0.000 description 8
230000003197 catalytic effect Effects 0.000 description 8
239000011248 coating agent Substances 0.000 description 8
230000002939 deleterious effect Effects 0.000 description 8
229920001223 polyethylene glycol Polymers 0.000 description 8
239000000758 substrate Substances 0.000 description 8
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 7
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
230000027455 binding Effects 0.000 description 7
238000003818 flash chromatography Methods 0.000 description 7
239000008101 lactose Substances 0.000 description 7
AMDDOQIUPAINLH-UHFFFAOYSA-N methyl 2-(3-hydroxyphenyl)acetate Chemical compound COC(=O)CC1=CC=CC(O)=C1 AMDDOQIUPAINLH-UHFFFAOYSA-N 0.000 description 7
239000012044 organic layer Substances 0.000 description 7
238000010898 silica gel chromatography Methods 0.000 description 7
239000011734 sodium Substances 0.000 description 7
238000003756 stirring Methods 0.000 description 7
239000000126 substance Substances 0.000 description 7
102000013498 tau Proteins Human genes 0.000 description 7
108010026424 tau Proteins Proteins 0.000 description 7
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
VADPVNJGSCOHEE-UHFFFAOYSA-N 2-[3-[3-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]propoxy]phenyl]acetic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CCCOC1=CC=CC(CC(O)=O)=C1 VADPVNJGSCOHEE-UHFFFAOYSA-N 0.000 description 6
INCBXEAXJJDWKH-UHFFFAOYSA-N 2-chloro-n-(4-pyridin-4-yl-1,3-thiazol-2-yl)acetamide Chemical compound S1C(NC(=O)CCl)=NC(C=2C=CN=CC=2)=C1 INCBXEAXJJDWKH-UHFFFAOYSA-N 0.000 description 6
QZIMUUMSYWILML-UHFFFAOYSA-N 5-pyridin-4-ylthiophen-3-amine Chemical compound NC1=CSC(C=2C=CN=CC=2)=C1 QZIMUUMSYWILML-UHFFFAOYSA-N 0.000 description 6
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
229920002527 Glycogen Polymers 0.000 description 6
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
150000001721 carbon Chemical group 0.000 description 6
238000011161 development Methods 0.000 description 6
230000014509 gene expression Effects 0.000 description 6
239000008103 glucose Substances 0.000 description 6
229940096919 glycogen Drugs 0.000 description 6
239000003102 growth factor Substances 0.000 description 6
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
229920000728 polyester Polymers 0.000 description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
238000000746 purification Methods 0.000 description 6
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
230000001105 regulatory effect Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
238000002390 rotary evaporation Methods 0.000 description 6
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
NFCJNZCDOQSEBH-UHFFFAOYSA-N tert-butyl 4-[3-[3-(2-methoxy-2-oxoethyl)phenoxy]propyl]piperidine-1-carboxylate Chemical compound COC(=O)CC1=CC=CC(OCCCC2CCN(CC2)C(=O)OC(C)(C)C)=C1 NFCJNZCDOQSEBH-UHFFFAOYSA-N 0.000 description 6
230000014616 translation Effects 0.000 description 6
238000005160 1H NMR spectroscopy Methods 0.000 description 5
WYJOVVXUZNRJQY-UHFFFAOYSA-N 2-Acetylthiophene Chemical compound CC(=O)C1=CC=CS1 WYJOVVXUZNRJQY-UHFFFAOYSA-N 0.000 description 5
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 5
108060000903 Beta-catenin Proteins 0.000 description 5
102000038030 PI3Ks Human genes 0.000 description 5
108091007960 PI3Ks Proteins 0.000 description 5
239000002202 Polyethylene glycol Substances 0.000 description 5
102000001708 Protein Isoforms Human genes 0.000 description 5
108010029485 Protein Isoforms Proteins 0.000 description 5
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
230000004663 cell proliferation Effects 0.000 description 5
230000004087 circulation Effects 0.000 description 5
238000001816 cooling Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
230000012010 growth Effects 0.000 description 5
125000005843 halogen group Chemical group 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 5
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 5
231100000252 nontoxic Toxicity 0.000 description 5
230000003000 nontoxic effect Effects 0.000 description 5
238000012360 testing method Methods 0.000 description 5
239000001993 wax Substances 0.000 description 5
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
MBWBHZYQZPLZRN-UHFFFAOYSA-N 1-(4-aminothiophen-2-yl)ethanone Chemical compound CC(=O)C1=CC(N)=CS1 MBWBHZYQZPLZRN-UHFFFAOYSA-N 0.000 description 4
MURKVQAOBMRVGL-UHFFFAOYSA-N 1-(4-nitrothiophen-2-yl)ethanone Chemical compound CC(=O)C1=CC([N+]([O-])=O)=CS1 MURKVQAOBMRVGL-UHFFFAOYSA-N 0.000 description 4
IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 4
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
PSCKJUURMCDVTQ-UHFFFAOYSA-N 2-[3-(3-chloropropoxy)phenyl]-n-(4-pyridin-4-yl-1,3-thiazol-2-yl)acetamide Chemical compound ClCCCOC1=CC=CC(CC(=O)NC=2SC=C(N=2)C=2C=CN=CC=2)=C1 PSCKJUURMCDVTQ-UHFFFAOYSA-N 0.000 description 4
VGGGBJOBOYIJBO-UHFFFAOYSA-N 2-[3-(3-chloropropoxy)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(OCCCCl)=C1 VGGGBJOBOYIJBO-UHFFFAOYSA-N 0.000 description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 4
NIEWDDIDOLYHOI-UHFFFAOYSA-N 3-phenyl-1-(4-pyridin-4-yl-1,3-thiazol-2-yl)piperazin-2-one Chemical compound O=C1C(C=2C=CC=CC=2)NCCN1C(SC=1)=NC=1C1=CC=NC=C1 NIEWDDIDOLYHOI-UHFFFAOYSA-N 0.000 description 4
102000015735 Beta-catenin Human genes 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
239000007995 HEPES buffer Substances 0.000 description 4
108010050904 Interferons Proteins 0.000 description 4
102000014150 Interferons Human genes 0.000 description 4
102000003855 L-lactate dehydrogenase Human genes 0.000 description 4
108700023483 L-lactate dehydrogenases Proteins 0.000 description 4
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
108700020796 Oncogene Proteins 0.000 description 4
206010033128 Ovarian cancer Diseases 0.000 description 4
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
108020005115 Pyruvate Kinase Proteins 0.000 description 4
102000013009 Pyruvate Kinase Human genes 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
208000027418 Wounds and injury Diseases 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
235000010443 alginic acid Nutrition 0.000 description 4
229920000615 alginic acid Polymers 0.000 description 4
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 4
239000012472 biological sample Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000003246 corticosteroid Substances 0.000 description 4
239000012043 crude product Substances 0.000 description 4
229960004397 cyclophosphamide Drugs 0.000 description 4
229940127089 cytotoxic agent Drugs 0.000 description 4
230000006378 damage Effects 0.000 description 4
UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 4
102000034356 gene-regulatory proteins Human genes 0.000 description 4
108091006104 gene-regulatory proteins Proteins 0.000 description 4
239000012362 glacial acetic acid Substances 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
239000005556 hormone Substances 0.000 description 4
239000003701 inert diluent Substances 0.000 description 4
208000014674 injury Diseases 0.000 description 4
210000003734 kidney Anatomy 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
239000002207 metabolite Substances 0.000 description 4
230000009826 neoplastic cell growth Effects 0.000 description 4
210000002682 neurofibrillary tangle Anatomy 0.000 description 4
229930029653 phosphoenolpyruvate Natural products 0.000 description 4
DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 4
229910052698 phosphorus Inorganic materials 0.000 description 4
239000011574 phosphorus Chemical group 0.000 description 4
239000006187 pill Substances 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000007909 solid dosage form Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
239000008107 starch Substances 0.000 description 4
239000007858 starting material Substances 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
239000003826 tablet Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
150000003557 thiazoles Chemical class 0.000 description 4
RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 4
238000002054 transplantation Methods 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 4
QJOQOGOBHHPLTG-UHFFFAOYSA-N 2-(2-hydroxyethylamino)-2-phenyl-n-(4-pyridin-4-yl-1,3-thiazol-2-yl)acetamide Chemical compound C=1C=CC=CC=1C(NCCO)C(=O)NC(SC=1)=NC=1C1=CC=NC=C1 QJOQOGOBHHPLTG-UHFFFAOYSA-N 0.000 description 3
HRFLULLBPLPBSW-UHFFFAOYSA-N 2-(3-ethoxyphenyl)acetic acid Chemical compound CCOC1=CC=CC(CC(O)=O)=C1 HRFLULLBPLPBSW-UHFFFAOYSA-N 0.000 description 3
RUGDYDBEYAHJCD-UHFFFAOYSA-N 2-(3-methylsulfonylphenyl)acetic acid Chemical compound CS(=O)(=O)C1=CC=CC(CC(O)=O)=C1 RUGDYDBEYAHJCD-UHFFFAOYSA-N 0.000 description 3
IMDMAPNWXDTADU-UHFFFAOYSA-N 2-[3-(3-piperidin-4-ylpropoxy)phenyl]-n-(4-pyridin-4-yl-1,3-thiazol-2-yl)acetamide Chemical compound N=1C(C=2C=CN=CC=2)=CSC=1NC(=O)CC(C=1)=CC=CC=1OCCCC1CCNCC1 IMDMAPNWXDTADU-UHFFFAOYSA-N 0.000 description 3
RGALBQILADNMKA-UHFFFAOYSA-N 2-bromo-1-pyridin-4-ylethanone;hydron;bromide Chemical compound Br.BrCC(=O)C1=CC=NC=C1 RGALBQILADNMKA-UHFFFAOYSA-N 0.000 description 3
RNIDWJDZNNVFDY-UHFFFAOYSA-N 3-Acetylthiophene Chemical compound CC(=O)C=1C=CSC=1 RNIDWJDZNNVFDY-UHFFFAOYSA-N 0.000 description 3
NJUFUBBHPBNHQJ-UHFFFAOYSA-N 3-chloro-3-pyridin-4-ylprop-2-enenitrile Chemical compound N#CC=C(Cl)C1=CC=NC=C1 NJUFUBBHPBNHQJ-UHFFFAOYSA-N 0.000 description 3
KRBQJJDPWOTAQA-UHFFFAOYSA-N 3-pyridin-4-yl-1,2,4-thiadiazol-5-amine Chemical compound S1C(N)=NC(C=2C=CN=CC=2)=N1 KRBQJJDPWOTAQA-UHFFFAOYSA-N 0.000 description 3
CSLYVMYZUKEDAH-UHFFFAOYSA-N 4-(5-nitrothiophen-3-yl)pyrimidine Chemical compound S1C([N+](=O)[O-])=CC(C=2N=CN=CC=2)=C1 CSLYVMYZUKEDAH-UHFFFAOYSA-N 0.000 description 3
MUMDXQWEIIXSQX-UHFFFAOYSA-N 4-thiophen-3-ylpyrimidine Chemical compound S1C=CC(C=2N=CN=CC=2)=C1 MUMDXQWEIIXSQX-UHFFFAOYSA-N 0.000 description 3
DIBGPCFGWOJKNP-UHFFFAOYSA-N 5-pyridin-4-ylthiophen-2-amine Chemical compound S1C(N)=CC=C1C1=CC=NC=C1 DIBGPCFGWOJKNP-UHFFFAOYSA-N 0.000 description 3
ONZFSDFZNMUVKA-UHFFFAOYSA-N 5-pyrimidin-4-ylthiophen-3-amine Chemical compound NC1=CSC(C=2N=CN=CC=2)=C1 ONZFSDFZNMUVKA-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
101710137189 Amyloid-beta A4 protein Proteins 0.000 description 3
102100022704 Amyloid-beta precursor protein Human genes 0.000 description 3
101710151993 Amyloid-beta precursor protein Proteins 0.000 description 3
101100025412 Arabidopsis thaliana XI-A gene Proteins 0.000 description 3
101100025413 Arabidopsis thaliana XI-B gene Proteins 0.000 description 3
101100025420 Arabidopsis thaliana XI-C gene Proteins 0.000 description 3
101100515508 Arabidopsis thaliana XI-D gene Proteins 0.000 description 3
101100515513 Arabidopsis thaliana XI-E gene Proteins 0.000 description 3
101100515514 Arabidopsis thaliana XI-F gene Proteins 0.000 description 3
206010006187 Breast cancer Diseases 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
101150041968 CDC13 gene Proteins 0.000 description 3
101100162366 Caenorhabditis elegans akt-2 gene Proteins 0.000 description 3
239000004215 Carbon black (E152) Substances 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
206010009944 Colon cancer Diseases 0.000 description 3
208000031124 Dementia Alzheimer type Diseases 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
208000012902 Nervous system disease Diseases 0.000 description 3
208000025966 Neurological disease Diseases 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
206010061902 Pancreatic neoplasm Diseases 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
208000017442 Retinal disease Diseases 0.000 description 3
206010038923 Retinopathy Diseases 0.000 description 3
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000010933 acylation Effects 0.000 description 3
238000005917 acylation reaction Methods 0.000 description 3
125000003342 alkenyl group Chemical group 0.000 description 3
125000003545 alkoxy group Chemical group 0.000 description 3
239000002585 base Substances 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
229960001334 corticosteroids Drugs 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000010511 deprotection reaction Methods 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
239000000945 filler Substances 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
239000011521 glass Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
229930195733 hydrocarbon Natural products 0.000 description 3
150000002430 hydrocarbons Chemical group 0.000 description 3
229940079322 interferon Drugs 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
BVKGNQRDVFGNIW-UHFFFAOYSA-N methyl 2-(3-aminophenyl)acetate Chemical compound COC(=O)CC1=CC=CC(N)=C1 BVKGNQRDVFGNIW-UHFFFAOYSA-N 0.000 description 3
QGYXFRVODXAEPB-UHFFFAOYSA-N methyl 2-(3-ethoxyphenyl)acetate Chemical compound CCOC1=CC=CC(CC(=O)OC)=C1 QGYXFRVODXAEPB-UHFFFAOYSA-N 0.000 description 3
PLOWZCWDZYYNNV-UHFFFAOYSA-N methyl 2-(3-methylsulfonylphenyl)acetate Chemical compound COC(=O)CC1=CC=CC(S(C)(=O)=O)=C1 PLOWZCWDZYYNNV-UHFFFAOYSA-N 0.000 description 3
XATOZTUIIMWMSB-UHFFFAOYSA-N methyl 2-[3-(3-chloropropoxy)phenyl]acetate Chemical compound COC(=O)CC1=CC=CC(OCCCCl)=C1 XATOZTUIIMWMSB-UHFFFAOYSA-N 0.000 description 3
239000003226 mitogen Substances 0.000 description 3
BFLSEPDIKRQHPR-UHFFFAOYSA-N n-(2-amino-2-oxoethyl)pyridine-4-carboxamide Chemical compound NC(=O)CNC(=O)C1=CC=NC=C1 BFLSEPDIKRQHPR-UHFFFAOYSA-N 0.000 description 3
125000001624 naphthyl group Chemical group 0.000 description 3
230000004770 neurodegeneration Effects 0.000 description 3
235000021317 phosphate Nutrition 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
210000002307 prostate Anatomy 0.000 description 3
238000001243 protein synthesis Methods 0.000 description 3
238000001959 radiotherapy Methods 0.000 description 3
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
230000019491 signal transduction Effects 0.000 description 3
229910052710 silicon Chemical group 0.000 description 3
239000010703 silicon Chemical group 0.000 description 3
229960002930 sirolimus Drugs 0.000 description 3
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
239000008247 solid mixture Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
PMIOQDYICSDLCO-UHFFFAOYSA-N tert-butyl n-(5-acetylthiophen-3-yl)carbamate Chemical compound CC(=O)C1=CC(NC(=O)OC(C)(C)C)=CS1 PMIOQDYICSDLCO-UHFFFAOYSA-N 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
CDOOQLDZGMQWQC-HWKANZROSA-N (e)-3-(dimethylamino)-1-thiophen-3-ylprop-2-en-1-one Chemical compound CN(C)\C=C\C(=O)C=1C=CSC=1 CDOOQLDZGMQWQC-HWKANZROSA-N 0.000 description 2
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
OMMZSDGGKVRGGP-UHFFFAOYSA-N 1-methylsulfonylbenzotriazole Chemical compound C1=CC=C2N(S(=O)(=O)C)N=NC2=C1 OMMZSDGGKVRGGP-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
MVPBZRJYKLUYQK-UHFFFAOYSA-N 2-(2-fluorophenyl)-n-(3-pyridin-4-yl-1,2,4-thiadiazol-5-yl)acetamide Chemical compound FC1=CC=CC=C1CC(=O)NC1=NC(C=2C=CN=CC=2)=NS1 MVPBZRJYKLUYQK-UHFFFAOYSA-N 0.000 description 2
IPVKLYGTZYLMKE-UHFFFAOYSA-N 2-(2-fluorophenyl)-n-(4-pyridin-4-yl-1,3-thiazol-2-yl)acetamide Chemical compound FC1=CC=CC=C1CC(=O)NC1=NC(C=2C=CN=CC=2)=CS1 IPVKLYGTZYLMKE-UHFFFAOYSA-N 0.000 description 2
RPTRFSADOICSSK-UHFFFAOYSA-N 2-(2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1F RPTRFSADOICSSK-UHFFFAOYSA-N 0.000 description 2
GOPDRFODUBCWMB-UHFFFAOYSA-N 2-(3-methoxyphenyl)-n-(4-pyridin-4-yl-1,3-thiazol-2-yl)acetamide Chemical compound COC1=CC=CC(CC(=O)NC=2SC=C(N=2)C=2C=CN=CC=2)=C1 GOPDRFODUBCWMB-UHFFFAOYSA-N 0.000 description 2
QOQVJBWXUNJCSG-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-(4-pyrimidin-4-ylthiophen-2-yl)acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC1=CC(C=2N=CN=CC=2)=CS1 QOQVJBWXUNJCSG-UHFFFAOYSA-N 0.000 description 2
XAAJDTGLCRACAV-UHFFFAOYSA-N 2-(benzenesulfinyl)-n-(4-pyridin-4-yl-1,3-thiazol-2-yl)acetamide Chemical compound N=1C(C=2C=CN=CC=2)=CSC=1NC(=O)CS(=O)C1=CC=CC=C1 XAAJDTGLCRACAV-UHFFFAOYSA-N 0.000 description 2
FWGRPYMVNJBTHK-UHFFFAOYSA-N 2-(benzenesulfonyl)-n-(4-pyridin-4-yl-1,3-thiazol-2-yl)acetamide Chemical compound N=1C(C=2C=CN=CC=2)=CSC=1NC(=O)CS(=O)(=O)C1=CC=CC=C1 FWGRPYMVNJBTHK-UHFFFAOYSA-N 0.000 description 2
LZXREMSLLLKFGQ-UHFFFAOYSA-N 2-[3-(2-chloroethoxy)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(OCCCl)=C1 LZXREMSLLLKFGQ-UHFFFAOYSA-N 0.000 description 2
ZTCBEQREBSKZPR-UHFFFAOYSA-N 2-amino-5-pyridin-4-ylthiophene-3-carboxylic acid Chemical compound OC(=O)C1=C(N)SC(C=2C=CN=CC=2)=C1 ZTCBEQREBSKZPR-UHFFFAOYSA-N 0.000 description 2
KQYGMMSPHNAULM-UHFFFAOYSA-N 2-phenylsulfanyl-n-(4-pyridin-4-yl-1,3-thiazol-2-yl)acetamide Chemical compound N=1C(C=2C=CN=CC=2)=CSC=1NC(=O)CSC1=CC=CC=C1 KQYGMMSPHNAULM-UHFFFAOYSA-N 0.000 description 2
XDSZLRLNLNJICE-UHFFFAOYSA-N 2-pyridin-4-yl-1,3-thiazol-5-amine Chemical compound S1C(N)=CN=C1C1=CC=NC=C1 XDSZLRLNLNJICE-UHFFFAOYSA-N 0.000 description 2
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
ULFBOWKRIWQPTO-UHFFFAOYSA-N 3-(3-methoxyphenyl)-1-(4-pyridin-4-yl-1,3-thiazol-2-yl)piperidin-2-one Chemical compound COC1=CC=CC(C2C(N(C=3SC=C(N=3)C=3C=CN=CC=3)CCC2)=O)=C1 ULFBOWKRIWQPTO-UHFFFAOYSA-N 0.000 description 2
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
LEGPZHPSIPPYIO-UHFFFAOYSA-N 3-Methoxyphenylacetic acid Chemical compound COC1=CC=CC(CC(O)=O)=C1 LEGPZHPSIPPYIO-UHFFFAOYSA-N 0.000 description 2
KLKGICPGTDUYLZ-UHFFFAOYSA-N 3-amino-5-pyridin-4-ylthiophene-2-carboxylic acid Chemical compound S1C(C(O)=O)=C(N)C=C1C1=CC=NC=C1 KLKGICPGTDUYLZ-UHFFFAOYSA-N 0.000 description 2
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
FVMDYYGIDFPZAX-UHFFFAOYSA-N 3-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=CC(O)=C1 FVMDYYGIDFPZAX-UHFFFAOYSA-N 0.000 description 2
WOKPTKZNKYUTHL-UHFFFAOYSA-N 3-phenyl-n-(5-pyridin-4-ylthiophen-3-yl)propanamide Chemical compound C=1SC(C=2C=CN=CC=2)=CC=1NC(=O)CCC1=CC=CC=C1 WOKPTKZNKYUTHL-UHFFFAOYSA-N 0.000 description 2
DBIMLJDSPUCGGY-UHFFFAOYSA-N 3-piperidin-4-ylpropan-1-ol Chemical compound OCCCC1CCNCC1 DBIMLJDSPUCGGY-UHFFFAOYSA-N 0.000 description 2
JOMLTZHMVJFVKS-UHFFFAOYSA-N 3-pyridin-4-yl-1,2-thiazol-5-amine Chemical compound S1C(N)=CC(C=2C=CN=CC=2)=N1 JOMLTZHMVJFVKS-UHFFFAOYSA-N 0.000 description 2
FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 2
CZMBSPFWRYOPOP-UHFFFAOYSA-N 4-pyridin-4-ylthiophen-2-amine Chemical compound S1C(N)=CC(C=2C=CN=CC=2)=C1 CZMBSPFWRYOPOP-UHFFFAOYSA-N 0.000 description 2
RYEMNCSEPUHTFZ-UHFFFAOYSA-N 4-pyrimidin-4-ylthiophen-2-amine Chemical compound S1C(N)=CC(C=2N=CN=CC=2)=C1 RYEMNCSEPUHTFZ-UHFFFAOYSA-N 0.000 description 2
JIONTUFGYIIZCE-UHFFFAOYSA-N 4-pyrimidin-4-ylthiophen-2-amine;hydrochloride Chemical compound Cl.S1C(N)=CC(C=2N=CN=CC=2)=C1 JIONTUFGYIIZCE-UHFFFAOYSA-N 0.000 description 2
KTWDTPBHCWJWGJ-UHFFFAOYSA-N 5-pyridin-4-yl-1,3,4-thiadiazol-2-amine Chemical compound S1C(N)=NN=C1C1=CC=NC=C1 KTWDTPBHCWJWGJ-UHFFFAOYSA-N 0.000 description 2
HYLRTCZROVMKOX-UHFFFAOYSA-N 6-phenyl-4-(4-pyridin-4-yl-1,3-thiazol-2-yl)-2,3-dihydropyrazin-5-one Chemical compound O=C1N(C=2SC=C(N=2)C=2C=CN=CC=2)CCN=C1C1=CC=CC=C1 HYLRTCZROVMKOX-UHFFFAOYSA-N 0.000 description 2
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
208000037259 Amyloid Plaque Diseases 0.000 description 2
102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
101100347605 Arabidopsis thaliana VIII-A gene Proteins 0.000 description 2
101100347612 Arabidopsis thaliana VIII-B gene Proteins 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
208000020925 Bipolar disease Diseases 0.000 description 2
101100322915 Caenorhabditis elegans akt-1 gene Proteins 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
102100030013 Endoribonuclease Human genes 0.000 description 2
101710199605 Endoribonuclease Proteins 0.000 description 2
108060006662 GSK3 Proteins 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
208000010412 Glaucoma Diseases 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
108010001483 Glycogen Synthase Proteins 0.000 description 2
239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
208000017604 Hodgkin disease Diseases 0.000 description 2
208000010747 Hodgkins lymphoma Diseases 0.000 description 2
101001129076 Homo sapiens Serine/threonine-protein kinase N1 Proteins 0.000 description 2
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 2
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
108010005716 Interferon beta-1a Proteins 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 2
102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 2
102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 2
102000015336 Nerve Growth Factor Human genes 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
102000014160 PTEN Phosphohydrolase Human genes 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
102000010995 Pleckstrin homology domains Human genes 0.000 description 2
108050001185 Pleckstrin homology domains Proteins 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 2
102000002278 Ribosomal Proteins Human genes 0.000 description 2
108010000605 Ribosomal Proteins Proteins 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
101710113029 Serine/threonine-protein kinase Proteins 0.000 description 2
102100031206 Serine/threonine-protein kinase N1 Human genes 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
102000013275 Somatomedins Human genes 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000013543 active substance Substances 0.000 description 2
235000010419 agar Nutrition 0.000 description 2
229940072056 alginate Drugs 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
229940024606 amino acid Drugs 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
125000003277 amino group Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000000074 antisense oligonucleotide Substances 0.000 description 2
238000012230 antisense oligonucleotides Methods 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
125000003710 aryl alkyl group Chemical group 0.000 description 2
125000005160 aryl oxy alkyl group Chemical group 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
229960002170 azathioprine Drugs 0.000 description 2
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
150000003935 benzaldehydes Chemical class 0.000 description 2
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
238000004166 bioassay Methods 0.000 description 2
229920002988 biodegradable polymer Polymers 0.000 description 2
239000004621 biodegradable polymer Substances 0.000 description 2
230000036765 blood level Effects 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000006172 buffering agent Substances 0.000 description 2
235000019437 butane-1,3-diol Nutrition 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
125000002837 carbocyclic group Chemical group 0.000 description 2
229910002091 carbon monoxide Inorganic materials 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
230000003915 cell function Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
230000008602 contraction Effects 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
235000005687 corn oil Nutrition 0.000 description 2
239000002285 corn oil Substances 0.000 description 2
235000012343 cottonseed oil Nutrition 0.000 description 2
239000002385 cottonseed oil Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
229940043264 dodecyl sulfate Drugs 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
239000008298 dragée Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
239000002702 enteric coating Substances 0.000 description 2
238000009505 enteric coating Methods 0.000 description 2
238000001952 enzyme assay Methods 0.000 description 2
LKLAPQXKZAVVPT-UHFFFAOYSA-N ethyl 2-amino-4-pyridin-4-ylthiophene-3-carboxylate Chemical compound CCOC(=O)C1=C(N)SC=C1C1=CC=NC=C1 LKLAPQXKZAVVPT-UHFFFAOYSA-N 0.000 description 2
LKBUBSZCCSFVKF-UHFFFAOYSA-N ethyl 2-amino-5-pyridin-4-ylthiophene-3-carboxylate Chemical compound S1C(N)=C(C(=O)OCC)C=C1C1=CC=NC=C1 LKBUBSZCCSFVKF-UHFFFAOYSA-N 0.000 description 2
LDRLPKPXMAOPME-UHFFFAOYSA-N ethyl 2-cyano-3-pyridin-4-ylbut-2-enoate Chemical compound CCOC(=O)C(C#N)=C(C)C1=CC=NC=C1 LDRLPKPXMAOPME-UHFFFAOYSA-N 0.000 description 2
ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 2
QPSXOHNGNAZYIS-UHFFFAOYSA-N ethyl 3-amino-5-pyridin-4-ylthiophene-2-carboxylate Chemical compound NC1=C(C(=O)OCC)SC(C=2C=CN=CC=2)=C1 QPSXOHNGNAZYIS-UHFFFAOYSA-N 0.000 description 2
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000012065 filter cake Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
208000005017 glioblastoma Diseases 0.000 description 2
230000004190 glucose uptake Effects 0.000 description 2
229940093915 gynecological organic acid Drugs 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
230000036541 health Effects 0.000 description 2
125000004475 heteroaralkyl group Chemical group 0.000 description 2
125000005114 heteroarylalkoxy group Chemical group 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 2
230000006951 hyperphosphorylation Effects 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000007972 injectable composition Substances 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
230000031146 intracellular signal transduction Effects 0.000 description 2
TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
229940043355 kinase inhibitor Drugs 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
239000012528 membrane Substances 0.000 description 2
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
208000030159 metabolic disease Diseases 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
SAWHRCMWTSAFCH-UHFFFAOYSA-N methyl 2-[3-(2-chloroethoxy)phenyl]acetate Chemical compound COC(=O)CC1=CC=CC(OCCCl)=C1 SAWHRCMWTSAFCH-UHFFFAOYSA-N 0.000 description 2
239000004530 micro-emulsion Substances 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
230000035772 mutation Effects 0.000 description 2
OWVFJYJLBSWYII-UHFFFAOYSA-N n,n-dimethyl-2-pyridin-4-ylethenamine Chemical compound CN(C)C=CC1=CC=NC=C1 OWVFJYJLBSWYII-UHFFFAOYSA-N 0.000 description 2
NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 2
FWHVRDRIMGMYKV-UHFFFAOYSA-N n-ethyl-4-pyridin-4-yl-1,3-thiazol-2-amine Chemical compound S1C(NCC)=NC(C=2C=CN=CC=2)=C1 FWHVRDRIMGMYKV-UHFFFAOYSA-N 0.000 description 2
LNSHQUCKCGOJHL-UHFFFAOYSA-N n-methyl-4-pyridin-4-yl-1,3-thiazol-2-amine Chemical compound S1C(NC)=NC(C=2C=CN=CC=2)=C1 LNSHQUCKCGOJHL-UHFFFAOYSA-N 0.000 description 2
229940053128 nerve growth factor Drugs 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
150000002823 nitrates Chemical class 0.000 description 2
239000000346 nonvolatile oil Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
239000003605 opacifier Substances 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 2
208000008443 pancreatic carcinoma Diseases 0.000 description 2
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical group OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
239000003757 phosphotransferase inhibitor Substances 0.000 description 2
230000010118 platelet activation Effects 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
238000012746 preparative thin layer chromatography Methods 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
229960004063 propylene glycol Drugs 0.000 description 2
238000005956 quaternization reaction Methods 0.000 description 2
230000005855 radiation Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
230000000698 schizophrenic effect Effects 0.000 description 2
238000013207 serial dilution Methods 0.000 description 2
239000008159 sesame oil Substances 0.000 description 2
235000011803 sesame oil Nutrition 0.000 description 2
230000035939 shock Effects 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
230000016160 smooth muscle contraction Effects 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
229960001940 sulfasalazine Drugs 0.000 description 2
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
OXPWHPCCUXESFQ-UHFFFAOYSA-N tert-butyl 4-(3-hydroxypropyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CCCO)CC1 OXPWHPCCUXESFQ-UHFFFAOYSA-N 0.000 description 2
LJOPALNCHWSQON-UHFFFAOYSA-N tert-butyl n-[5-[3-(dimethylamino)prop-2-enoyl]thiophen-3-yl]carbamate Chemical compound CN(C)C=CC(=O)C1=CC(NC(=O)OC(C)(C)C)=CS1 LJOPALNCHWSQON-UHFFFAOYSA-N 0.000 description 2
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
125000004001 thioalkyl group Chemical group 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 2
FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
230000002792 vascular Effects 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
229940058015 1,3-butylene glycol Drugs 0.000 description 1
HPARLNRMYDSBNO-UHFFFAOYSA-N 1,4-benzodioxine Chemical compound C1=CC=C2OC=COC2=C1 HPARLNRMYDSBNO-UHFFFAOYSA-N 0.000 description 1
YWWZASFPWWPUBN-UHFFFAOYSA-N 1-bromoisoquinoline Chemical compound C1=CC=C2C(Br)=NC=CC2=C1 YWWZASFPWWPUBN-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
ACULMSXMKICJIS-UHFFFAOYSA-N 1-phenyl-2-pyridin-4-ylethanone Chemical compound C=1C=CC=CC=1C(=O)CC1=CC=NC=C1 ACULMSXMKICJIS-UHFFFAOYSA-N 0.000 description 1
WMQUKDQWMMOHSA-UHFFFAOYSA-N 1-pyridin-4-ylethanone Chemical compound CC(=O)C1=CC=NC=C1 WMQUKDQWMMOHSA-UHFFFAOYSA-N 0.000 description 1
AJKKZEHIYREOFF-UHFFFAOYSA-N 1-thiophen-3-ylethanol Chemical compound CC(O)C=1C=CSC=1 AJKKZEHIYREOFF-UHFFFAOYSA-N 0.000 description 1
CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
XUSKZLBLGHBCLD-UHFFFAOYSA-N 2-(3-aminophenyl)acetic acid Chemical compound NC1=CC=CC(CC(O)=O)=C1 XUSKZLBLGHBCLD-UHFFFAOYSA-N 0.000 description 1
ZUXCSMLYGMFCSP-UHFFFAOYSA-N 2-(3-hydroxyphenyl)-n-(4-pyridin-4-yl-1,3-thiazol-2-yl)acetamide Chemical compound OC1=CC=CC(CC(=O)NC=2SC=C(N=2)C=2C=CN=CC=2)=C1 ZUXCSMLYGMFCSP-UHFFFAOYSA-N 0.000 description 1
VYHMGWKLVWNYCW-UHFFFAOYSA-N 2-(3-methoxyphenyl)-n-(3-piperazin-1-ylpropyl)-n-(4-pyridin-4-yl-1,3-thiazol-2-yl)acetamide Chemical compound COC1=CC=CC(CC(=O)N(CCCN2CCNCC2)C=2SC=C(N=2)C=2C=CN=CC=2)=C1 VYHMGWKLVWNYCW-UHFFFAOYSA-N 0.000 description 1
MGKPFALCNDRSQD-UHFFFAOYSA-N 2-(4-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C=C1 MGKPFALCNDRSQD-UHFFFAOYSA-N 0.000 description 1
UFPSPRUVVYPGMS-UHFFFAOYSA-N 2-(n-methylanilino)-n-(4-pyridin-4-yl-1,3-thiazol-2-yl)acetamide Chemical compound C=1C=CC=CC=1N(C)CC(=O)NC(SC=1)=NC=1C1=CC=NC=C1 UFPSPRUVVYPGMS-UHFFFAOYSA-N 0.000 description 1
MYQDOXCEVXCUIE-UHFFFAOYSA-N 2-[2-[tert-butyl(dimethyl)silyl]oxyethylamino]-2-phenyl-n-(4-pyridin-4-yl-1,3-thiazol-2-yl)acetamide Chemical compound C=1C=CC=CC=1C(NCCO[Si](C)(C)C(C)(C)C)C(=O)NC(SC=1)=NC=1C1=CC=NC=C1 MYQDOXCEVXCUIE-UHFFFAOYSA-N 0.000 description 1
XLMFBNMLEHYJGT-UHFFFAOYSA-N 2-[3-(3-piperazin-1-ylpropoxy)phenyl]-n-(4-pyridin-4-yl-1,3-thiazol-2-yl)acetamide Chemical compound N=1C(C=2C=CN=CC=2)=CSC=1NC(=O)CC(C=1)=CC=CC=1OCCCN1CCNCC1 XLMFBNMLEHYJGT-UHFFFAOYSA-N 0.000 description 1
HDPSXKQRUMBAOJ-UHFFFAOYSA-N 2-[3-[3-(1-ethylpiperidin-4-yl)propoxy]phenyl]-n-(4-pyridin-4-yl-1,3-thiazol-2-yl)acetamide Chemical compound C1CN(CC)CCC1CCCOC1=CC=CC(CC(=O)NC=2SC=C(N=2)C=2C=CN=CC=2)=C1 HDPSXKQRUMBAOJ-UHFFFAOYSA-N 0.000 description 1
JZOJZTZEIXHSQT-UHFFFAOYSA-N 2-[3-[3-(1-methylpiperidin-4-yl)propoxy]phenyl]-n-(4-pyridin-4-yl-1,3-thiazol-2-yl)acetamide Chemical compound C1CN(C)CCC1CCCOC1=CC=CC(CC(=O)NC=2SC=C(N=2)C=2C=CN=CC=2)=C1 JZOJZTZEIXHSQT-UHFFFAOYSA-N 0.000 description 1
WIGDGIGALMYEBW-LLINQDLYSA-N 2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O WIGDGIGALMYEBW-LLINQDLYSA-N 0.000 description 1
OFZRXKPNXVTQBB-UHFFFAOYSA-N 2-amino-2-phenyl-n-(4-pyridin-4-yl-1,3-thiazol-2-yl)acetamide Chemical compound C=1C=CC=CC=1C(N)C(=O)NC(SC=1)=NC=1C1=CC=NC=C1 OFZRXKPNXVTQBB-UHFFFAOYSA-N 0.000 description 1
WKNMKGVLOWGGOU-UHFFFAOYSA-N 2-aminoacetamide;hydron;chloride Chemical compound Cl.NCC(N)=O WKNMKGVLOWGGOU-UHFFFAOYSA-N 0.000 description 1
FEGCKHYVBPBELH-UHFFFAOYSA-N 2-anilino-n-(4-pyridin-4-yl-1,3-thiazol-2-yl)acetamide Chemical compound N=1C(C=2C=CN=CC=2)=CSC=1NC(=O)CNC1=CC=CC=C1 FEGCKHYVBPBELH-UHFFFAOYSA-N 0.000 description 1
229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
GTZRWNTWJYHRKN-UHFFFAOYSA-N 2-phenoxy-n-(4-pyridin-4-yl-1,3-thiazol-2-yl)acetamide Chemical compound N=1C(C=2C=CN=CC=2)=CSC=1NC(=O)COC1=CC=CC=C1 GTZRWNTWJYHRKN-UHFFFAOYSA-N 0.000 description 1
RLDJWBVOZVJJOS-UHFFFAOYSA-N 2-phenyl-2-(phenylmethoxycarbonylamino)acetic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)NC(=O)OCC1=CC=CC=C1 RLDJWBVOZVJJOS-UHFFFAOYSA-N 0.000 description 1
HXLWCOMRAKZZTG-UHFFFAOYSA-N 2-pyridin-4-yl-1,3-thiazol-4-amine Chemical compound NC1=CSC(C=2C=CN=CC=2)=N1 HXLWCOMRAKZZTG-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
PRRZDZJYSJLDBS-UHFFFAOYSA-N 3-bromo-2-oxopropanoic acid Chemical compound OC(=O)C(=O)CBr PRRZDZJYSJLDBS-UHFFFAOYSA-N 0.000 description 1
XCMISAPCWHTVNG-UHFFFAOYSA-N 3-bromothiophene Chemical compound BrC=1C=CSC=1 XCMISAPCWHTVNG-UHFFFAOYSA-N 0.000 description 1
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
HIHVJFDBWAVQNE-UHFFFAOYSA-N 3-piperidin-4-ylpropyl acetate Chemical compound CC(=O)OCCCC1CCNCC1 HIHVJFDBWAVQNE-UHFFFAOYSA-N 0.000 description 1
PZVZGDBCMQBRMA-UHFFFAOYSA-N 3-pyridin-4-ylpropan-1-ol Chemical compound OCCCC1=CC=NC=C1 PZVZGDBCMQBRMA-UHFFFAOYSA-N 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
LSANRJDFADGCSL-UHFFFAOYSA-N 4-pyridin-4-yl-1,3-thiazol-2-amine;dihydrobromide Chemical compound Br.Br.S1C(N)=NC(C=2C=CN=CC=2)=C1 LSANRJDFADGCSL-UHFFFAOYSA-N 0.000 description 1
QMYONSKHCULDQQ-UHFFFAOYSA-N 4-pyridin-4-yl-1,3-thiazole Chemical compound S1C=NC(C=2C=CN=CC=2)=C1 QMYONSKHCULDQQ-UHFFFAOYSA-N 0.000 description 1
KNMAZUXTEPXPOM-UHFFFAOYSA-N 5-methoxy-6-(trifluoromethyl)-1h-indole Chemical compound C1=C(C(F)(F)F)C(OC)=CC2=C1NC=C2 KNMAZUXTEPXPOM-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
102000004146 ATP citrate synthases Human genes 0.000 description 1
108090000662 ATP citrate synthases Proteins 0.000 description 1
108091006112 ATPases Proteins 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
208000003200 Adenoma Diseases 0.000 description 1
206010001233 Adenoma benign Diseases 0.000 description 1
102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
229940126638 Akt inhibitor Drugs 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
108091006515 Anion channels Proteins 0.000 description 1
102000037829 Anion channels Human genes 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010004593 Bile duct cancer Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
ISSWZTVFZAXEOH-UHFFFAOYSA-N C(C1=CC=NC=C1)(=S)N.N1=CC=C(C=C1)C=1SC=C(N1)C(=O)O Chemical compound C(C1=CC=NC=C1)(=S)N.N1=CC=C(C=C1)C=1SC=C(N1)C(=O)O ISSWZTVFZAXEOH-UHFFFAOYSA-N 0.000 description 1
IKFLLHVVKJTHAH-UHFFFAOYSA-N CC1SC(N)=NC1 Chemical compound CC1SC(N)=NC1 IKFLLHVVKJTHAH-UHFFFAOYSA-N 0.000 description 1
125000006414 CCl Chemical group ClC* 0.000 description 1
KOHFPQBWSVANFX-UHFFFAOYSA-N CNc1cc(-c2ccccc2)c[s]1 Chemical compound CNc1cc(-c2ccccc2)c[s]1 KOHFPQBWSVANFX-UHFFFAOYSA-N 0.000 description 1
OIHGGFMJDWWPDV-UHFFFAOYSA-N COc(cc1)cc(CC(Nc2nc(C3=CCCC=C3)c[s]2)=O)c1OC Chemical compound COc(cc1)cc(CC(Nc2nc(C3=CCCC=C3)c[s]2)=O)c1OC OIHGGFMJDWWPDV-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
229920001268 Cholestyramine Polymers 0.000 description 1
206010008748 Chorea Diseases 0.000 description 1
241000723346 Cinnamomum camphora Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
240000004307 Citrus medica Species 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
102100023033 Cyclic AMP-dependent transcription factor ATF-2 Human genes 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
208000014094 Dystonic disease Diseases 0.000 description 1
239000012824 ERK inhibitor Substances 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
206010048554 Endothelial dysfunction Diseases 0.000 description 1
102000002045 Endothelin Human genes 0.000 description 1
108050009340 Endothelin Proteins 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
201000011240 Frontotemporal dementia Diseases 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
241000206672 Gelidium Species 0.000 description 1
108010072051 Glatiramer Acetate Proteins 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
102100021888 Helix-loop-helix protein 1 Human genes 0.000 description 1
206010073069 Hepatic cancer Diseases 0.000 description 1
208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
108010025076 Holoenzymes Proteins 0.000 description 1
101000894883 Homo sapiens Beta-secretase 2 Proteins 0.000 description 1
101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 description 1
101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
101000897691 Homo sapiens Helix-loop-helix protein 1 Proteins 0.000 description 1
101000610537 Homo sapiens Prokineticin-1 Proteins 0.000 description 1
101000691459 Homo sapiens Serine/threonine-protein kinase N2 Proteins 0.000 description 1
101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108030003815 Inositol 3-kinases Proteins 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
108090000862 Ion Channels Proteins 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
206010023347 Keratoacanthoma Diseases 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
239000005517 L01XE01 - Imatinib Substances 0.000 description 1
102000006835 Lamins Human genes 0.000 description 1
108010047294 Lamins Proteins 0.000 description 1
206010023825 Laryngeal cancer Diseases 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
208000035561 Leukaemic infiltration brain Diseases 0.000 description 1
108010000817 Leuprolide Proteins 0.000 description 1
206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
206010062038 Lip neoplasm Diseases 0.000 description 1
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
208000018501 Lymphatic disease Diseases 0.000 description 1
102000002569 MAP Kinase Kinase 4 Human genes 0.000 description 1
108010068304 MAP Kinase Kinase 4 Proteins 0.000 description 1
102000043136 MAP kinase family Human genes 0.000 description 1
108091054455 MAP kinase family Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
101710115937 Microtubule-associated protein tau Proteins 0.000 description 1
102100040243 Microtubule-associated protein tau Human genes 0.000 description 1
102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
208000003445 Mouth Neoplasms Diseases 0.000 description 1
208000016285 Movement disease Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010028570 Myelopathy Diseases 0.000 description 1
108010037801 Myosin-Light-Chain Phosphatase Proteins 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
KQJQICVXLJTWQD-UHFFFAOYSA-N N-Methylthiourea Chemical compound CNC(N)=S KQJQICVXLJTWQD-UHFFFAOYSA-N 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
GMEHFXXZSWDEDB-UHFFFAOYSA-N N-ethylthiourea Chemical compound CCNC(N)=S GMEHFXXZSWDEDB-UHFFFAOYSA-N 0.000 description 1
XGEGHDBEHXKFPX-UHFFFAOYSA-N N-methylthiourea Natural products CNC(N)=O XGEGHDBEHXKFPX-UHFFFAOYSA-N 0.000 description 1
INGVBFUZFULYRY-PTNGSMBKSA-N N/C(/c1ccncc1)=C\SC(C1)C1NC(CSc1ccccc1)=O Chemical compound N/C(/c1ccncc1)=C\SC(C1)C1NC(CSc1ccccc1)=O INGVBFUZFULYRY-PTNGSMBKSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
WGFHRZJMFQLQLJ-UHFFFAOYSA-N O=C(C(C1CC=CCC1)NCC1)N1C1SC=C(C2=CCNC=C2)N1 Chemical compound O=C(C(C1CC=CCC1)NCC1)N1C1SC=C(C2=CCNC=C2)N1 WGFHRZJMFQLQLJ-UHFFFAOYSA-N 0.000 description 1
MFEILWXBDBCWKF-UHFFFAOYSA-N O=C(CCc1ccccc1)Cl Chemical compound O=C(CCc1ccccc1)Cl MFEILWXBDBCWKF-UHFFFAOYSA-N 0.000 description 1
VKXUCUNZGYOPAJ-UHFFFAOYSA-N O=C(CCl)NC(SC1)=NC1c1ccncc1 Chemical compound O=C(CCl)NC(SC1)=NC1c1ccncc1 VKXUCUNZGYOPAJ-UHFFFAOYSA-N 0.000 description 1
SRENRNHMGROGOZ-UHFFFAOYSA-N O=C(c(cc1)cc(C2NCCc3c2cccc3)c1S)Nc1nc(-c2ccncc2)c[s]1 Chemical compound O=C(c(cc1)cc(C2NCCc3c2cccc3)c1S)Nc1nc(-c2ccncc2)c[s]1 SRENRNHMGROGOZ-UHFFFAOYSA-N 0.000 description 1
XDMFNGDBNKETMP-UHFFFAOYSA-N OC(C(CCC1)C2C=CC(F)=CC2F)N1C(SC1)=NC1c1ccncc1 Chemical compound OC(C(CCC1)C2C=CC(F)=CC2F)N1C(SC1)=NC1c1ccncc1 XDMFNGDBNKETMP-UHFFFAOYSA-N 0.000 description 1
ITRDUVZLQRRBCA-UHFFFAOYSA-O OC(C(CCC1)c2ccccc2)N1C1SCC(C2=CCNC=C2)[NH2+]1 Chemical compound OC(C(CCC1)c2ccccc2)N1C1SCC(C2=CCNC=C2)[NH2+]1 ITRDUVZLQRRBCA-UHFFFAOYSA-O 0.000 description 1
OHEQKKRZMQFFLA-UHFFFAOYSA-N OC(C(c1ccccc1)=NC1)N1c1nc(C2=CCNC=C2)c[s]1 Chemical compound OC(C(c1ccccc1)=NC1)N1c1nc(C2=CCNC=C2)c[s]1 OHEQKKRZMQFFLA-UHFFFAOYSA-N 0.000 description 1
FCIXBNFOHULFGG-UHFFFAOYSA-N OC(Cc1cccc(F)c1)NC1SC=C(C2=CCNC=C2)N1 Chemical compound OC(Cc1cccc(F)c1)NC1SC=C(C2=CCNC=C2)N1 FCIXBNFOHULFGG-UHFFFAOYSA-N 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
AAUCSFGSACZRQQ-UHFFFAOYSA-K P(=O)([O-])([O-])[O-].C(CCCCCCCCCCCCCCCCC)[Mg+].C(CCCCCCCCCCCCCCCCC)[Mg+].C(CCCCCCCCCCCCCCCCC)[Mg+] Chemical compound P(=O)([O-])([O-])[O-].C(CCCCCCCCCCCCCCCCC)[Mg+].C(CCCCCCCCCCCCCCCCC)[Mg+].C(CCCCCCCCCCCCCCCCC)[Mg+] AAUCSFGSACZRQQ-UHFFFAOYSA-K 0.000 description 1
229940124611 PDK1 inhibitor Drugs 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
102000005877 Peptide Initiation Factors Human genes 0.000 description 1
108010044843 Peptide Initiation Factors Proteins 0.000 description 1
208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
208000000609 Pick Disease of the Brain Diseases 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
108010013381 Porins Proteins 0.000 description 1
102000017033 Porins Human genes 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000015499 Presenilins Human genes 0.000 description 1
108010050254 Presenilins Proteins 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
102000003923 Protein Kinase C Human genes 0.000 description 1
108090000315 Protein Kinase C Proteins 0.000 description 1
YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
108010045717 Proto-Oncogene Proteins c-akt Proteins 0.000 description 1
108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 description 1
102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
102100039314 Rho-associated protein kinase 2 Human genes 0.000 description 1
101710088493 Rho-associated protein kinase 2 Proteins 0.000 description 1
108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 1
102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 1
102000003861 Ribosomal protein S6 Human genes 0.000 description 1
108090000221 Ribosomal protein S6 Proteins 0.000 description 1
FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
201000010208 Seminoma Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
102100026180 Serine/threonine-protein kinase N2 Human genes 0.000 description 1
102100037764 Serine/threonine-protein phosphatase PP1-beta catalytic subunit Human genes 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
102000018410 Small GTPase Rho Human genes 0.000 description 1
108050007506 Small GTPase Rho Proteins 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
206010062129 Tongue neoplasm Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
108700009124 Transcription Initiation Site Proteins 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
102100023132 Transcription factor Jun Human genes 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
206010064390 Tumour invasion Diseases 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
208000018839 Wilson disease Diseases 0.000 description 1
239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
KYFPJAXUCKOIKL-UHFFFAOYSA-N [3-[2-oxo-2-[(4-pyridin-4-yl-1,3-thiazol-2-yl)amino]ethyl]phenyl] methanesulfonate Chemical compound CS(=O)(=O)OC1=CC=CC(CC(=O)NC=2SC=C(N=2)C=2C=CN=CC=2)=C1 KYFPJAXUCKOIKL-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000003655 absorption accelerator Substances 0.000 description 1
SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 description 1
WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
239000008272 agar Substances 0.000 description 1
210000005057 airway smooth muscle cell Anatomy 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
150000008052 alkyl sulfonates Chemical class 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
229940035678 anti-parkinson drug Drugs 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
239000000063 antileukemic agent Substances 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
210000003433 aortic smooth muscle cell Anatomy 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
229940003504 avonex Drugs 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
210000004227 basal ganglia Anatomy 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 description 1
QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
239000012964 benzotriazole Substances 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
ZNSUDNIOJOQBMK-UHFFFAOYSA-N benzyl n-[2-oxo-1-phenyl-2-[(4-pyridin-4-yl-1,3-thiazol-2-yl)amino]ethyl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC(C=1C=CC=CC=1)C(=O)NC(SC=1)=NC=1C1=CC=NC=C1 ZNSUDNIOJOQBMK-UHFFFAOYSA-N 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
208000026900 bile duct neoplasm Diseases 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
208000028683 bipolar I disease Diseases 0.000 description 1
201000001531 bladder carcinoma Diseases 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000002725 brachytherapy Methods 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
229960002802 bromocriptine Drugs 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
229960000846 camphor Drugs 0.000 description 1
229930008380 camphor Natural products 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
239000003560 cancer drug Substances 0.000 description 1
230000009400 cancer invasion Effects 0.000 description 1
239000012830 cancer therapeutic Substances 0.000 description 1
229960004205 carbidopa Drugs 0.000 description 1
TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229960005243 carmustine Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000036978 cell physiology Effects 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
230000023715 cellular developmental process Effects 0.000 description 1
230000008727 cellular glucose uptake Effects 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
230000004637 cellular stress Effects 0.000 description 1
230000006364 cellular survival Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
201000007455 central nervous system cancer Diseases 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
201000010039 central nervous system leukemia Diseases 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
229910052729 chemical element Inorganic materials 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
KQDDQXNVESLJNO-UHFFFAOYSA-N chloromethanesulfonyl chloride Chemical compound ClCS(Cl)(=O)=O KQDDQXNVESLJNO-UHFFFAOYSA-N 0.000 description 1
208000006990 cholangiocarcinoma Diseases 0.000 description 1
239000000544 cholinesterase inhibitor Substances 0.000 description 1
208000012601 choreatic disease Diseases 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
108010060348 citron-kinase Proteins 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000035602 clotting Effects 0.000 description 1
239000011436 cob Substances 0.000 description 1
230000006999 cognitive decline Effects 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000010835 comparative analysis Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229940038717 copaxone Drugs 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
239000006071 cream Substances 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
230000003436 cytoskeletal effect Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
150000001982 diacylglycerols Chemical class 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
239000000539 dimer Substances 0.000 description 1
MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
235000019797 dipotassium phosphate Nutrition 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000006196 drop Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
208000010118 dystonia Diseases 0.000 description 1
239000003221 ear drop Substances 0.000 description 1
229940047652 ear drops Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000010894 electron beam technology Methods 0.000 description 1
238000009261 endocrine therapy Methods 0.000 description 1
229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
230000008694 endothelial dysfunction Effects 0.000 description 1
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
230000037149 energy metabolism Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
229960003337 entacapone Drugs 0.000 description 1
YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
229940093499 ethyl acetate Drugs 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
230000029142 excretion Effects 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000013100 final test Methods 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
229960002074 flutamide Drugs 0.000 description 1
230000004907 flux Effects 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
GTCCMGFBIWUBLQ-UHFFFAOYSA-N formamide;hydrochloride Chemical compound Cl.NC=O GTCCMGFBIWUBLQ-UHFFFAOYSA-N 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
210000001652 frontal lobe Anatomy 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
238000012224 gene deletion Methods 0.000 description 1
238000003197 gene knockdown Methods 0.000 description 1
238000003209 gene knockout Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229940080856 gleevec Drugs 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
125000000262 haloalkenyl group Chemical group 0.000 description 1
125000004438 haloalkoxy group Chemical group 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
210000003128 head Anatomy 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
UKJFVOWPUXSBOM-UHFFFAOYSA-N hexane;oxolane Chemical compound C1CCOC1.CCCCCC UKJFVOWPUXSBOM-UHFFFAOYSA-N 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
150000001261 hydroxy acids Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
150000002475 indoles Chemical class 0.000 description 1
LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical class C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
229910001410 inorganic ion Inorganic materials 0.000 description 1
230000006362 insulin response pathway Effects 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
229960004768 irinotecan Drugs 0.000 description 1
230000007794 irritation Effects 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
108010082683 kemptide Proteins 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229960000448 lactic acid Drugs 0.000 description 1
229940099584 lactobionate Drugs 0.000 description 1
JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
210000005053 lamin Anatomy 0.000 description 1
208000003849 large cell carcinoma Diseases 0.000 description 1
206010023841 laryngeal neoplasm Diseases 0.000 description 1
229940033355 lauric acid Drugs 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
229960004338 leuprorelin Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
201000006721 lip cancer Diseases 0.000 description 1
230000004576 lipid-binding Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
201000002250 liver carcinoma Diseases 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
201000005249 lung adenocarcinoma Diseases 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
229940049920 malate Drugs 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical group OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
230000015654 memory Effects 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
208000021039 metastatic melanoma Diseases 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
229960005127 montelukast Drugs 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
230000004899 motility Effects 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
229960004866 mycophenolate mofetil Drugs 0.000 description 1
HXRAMSFGUAOAJR-UHFFFAOYSA-N n,n,n',n'-tetramethyl-1-[(2-methylpropan-2-yl)oxy]methanediamine Chemical compound CN(C)C(N(C)C)OC(C)(C)C HXRAMSFGUAOAJR-UHFFFAOYSA-N 0.000 description 1
MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
OEHLKQKJNCVYPB-UHFFFAOYSA-N n-ethyl-4-pyridin-4-yl-1,3-thiazol-2-amine;dihydrobromide Chemical compound Br.Br.S1C(NCC)=NC(C=2C=CN=CC=2)=C1 OEHLKQKJNCVYPB-UHFFFAOYSA-N 0.000 description 1
PWDSPVORMDQASR-UHFFFAOYSA-N n-methyl-4-pyridin-4-yl-1,3-thiazol-2-amine;dihydrobromide Chemical compound Br.Br.S1C(NC)=NC(C=2C=CN=CC=2)=C1 PWDSPVORMDQASR-UHFFFAOYSA-N 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
230000027405 negative regulation of phosphorylation Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000016273 neuron death Effects 0.000 description 1
230000011242 neutrophil chemotaxis Effects 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
102000027450 oncoproteins Human genes 0.000 description 1
108091008819 oncoproteins Proteins 0.000 description 1
229940041678 oral spray Drugs 0.000 description 1
239000000668 oral spray Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
201000010198 papillary carcinoma Diseases 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000002304 perfume Substances 0.000 description 1
YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
229960004851 pergolide Drugs 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
210000003800 pharynx Anatomy 0.000 description 1
201000008006 pharynx cancer Diseases 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
229960003424 phenylacetic acid Drugs 0.000 description 1
239000003279 phenylacetic acid Substances 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
125000001095 phosphatidyl group Chemical group 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
230000000865 phosphorylative effect Effects 0.000 description 1
229940075930 picrate Drugs 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
229950010765 pivalate Drugs 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
229960001237 podophyllotoxin Drugs 0.000 description 1
YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
239000004632 polycaprolactone Substances 0.000 description 1
229920001610 polycaprolactone Polymers 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
108010037555 polypeptide 1 70kD ribosomal protein S6 kinase Proteins 0.000 description 1
229920000137 polyphosphoric acid Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
150000004804 polysaccharides Chemical class 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000004302 potassium sorbate Substances 0.000 description 1
235000010241 potassium sorbate Nutrition 0.000 description 1
229940069338 potassium sorbate Drugs 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
229950008679 protamine sulfate Drugs 0.000 description 1
239000012656 protein kinase A inhibitor Substances 0.000 description 1
229940043437 protein kinase A inhibitor Drugs 0.000 description 1
239000003197 protein kinase B inhibitor Substances 0.000 description 1
239000003909 protein kinase inhibitor Substances 0.000 description 1
108010065251 protein kinase modulator Proteins 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
238000002661 proton therapy Methods 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
239000000649 purine antagonist Substances 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
GPHQHTOMRSGBNZ-UHFFFAOYSA-N pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC=C1 GPHQHTOMRSGBNZ-UHFFFAOYSA-N 0.000 description 1
239000003790 pyrimidine antagonist Substances 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
238000010791 quenching Methods 0.000 description 1
ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 description 1
125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
229940038850 rebif Drugs 0.000 description 1
238000011084 recovery Methods 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
230000009467 reduction Effects 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
230000008521 reorganization Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000003938 response to stress Effects 0.000 description 1
239000003340 retarding agent Substances 0.000 description 1
108010041788 rho-Associated Kinases Proteins 0.000 description 1
102000000568 rho-Associated Kinases Human genes 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
229960004181 riluzole Drugs 0.000 description 1
RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
229960001534 risperidone Drugs 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
235000013580 sausages Nutrition 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229940035004 seroquel Drugs 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
208000000649 small cell carcinoma Diseases 0.000 description 1
201000002314 small intestine cancer Diseases 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
GYBMSOFSBPZKCX-UHFFFAOYSA-N sodium;ethanol;ethanolate Chemical compound [Na+].CCO.CC[O-] GYBMSOFSBPZKCX-UHFFFAOYSA-N 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000007921 spray Substances 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000003860 storage Methods 0.000 description 1
210000003518 stress fiber Anatomy 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229960001967 tacrolimus Drugs 0.000 description 1
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
230000008685 targeting Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
210000001138 tear Anatomy 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
GDCSPCZJWMQSLC-UHFFFAOYSA-N tert-butyl 4-(1-hydroxypropyl)piperidine-1-carboxylate Chemical compound CCC(O)C1CCN(C(=O)OC(C)(C)C)CC1 GDCSPCZJWMQSLC-UHFFFAOYSA-N 0.000 description 1
RPIZLIYDDSDIBS-UHFFFAOYSA-N tert-butyl 4-[3-[3-[2-oxo-2-[(4-pyridin-4-yl-1,3-thiazol-2-yl)amino]ethyl]phenoxy]propyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CCCOC1=CC=CC(CC(=O)NC=2SC=C(N=2)C=2C=CN=CC=2)=C1 RPIZLIYDDSDIBS-UHFFFAOYSA-N 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
229940124788 therapeutic inhibitor Drugs 0.000 description 1
VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
150000003577 thiophenes Chemical class 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
238000004448 titration Methods 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
201000006134 tongue cancer Diseases 0.000 description 1
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
229960000303 topotecan Drugs 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000005945 translocation Effects 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
229910052722 tritium Chemical group 0.000 description 1
208000009999 tuberous sclerosis Diseases 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
208000010576 undifferentiated carcinoma Diseases 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
208000010570 urinary bladder carcinoma Diseases 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
229940070710 valerate Drugs 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
229910052720 vanadium Inorganic materials 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
229960002066 vinorelbine Drugs 0.000 description 1
210000002268 wool Anatomy 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1

JP2005502202A 2002-10-30 2003-10-30 Ｒｏｃｋおよび他のプロテインキナーゼとして有用な組成物 Withdrawn JP2006514684A (ja)